UPDATE: KeyBanc On PRA Health Sciences Also Notes 'By our models, PRAH should be able to generate revenue growth of 8%+ and EBITDA growth of 12%+ in 2020 even in the face of some integration headwinds at Symphony Health'
Benzinga_Newsdesk